Kezar Life Sciences, Inc. (NASDAQ:KZR – Free Report) – Equities researchers at William Blair increased their Q2 2025 EPS estimates for Kezar Life Sciences in a note issued to investors on Tuesday, Ma… [+3273 chars]...
Read moreRenaissance Technologies LLC lessened its stake in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR – Free Report) by 93.2% in the 4th quarter, according to its most recent disclosure with the SEC. Th… [+3147 chars]...
Read moreKezar Life Sciences (NASDAQ:KZR – Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce ea… [+2038 chars]...
Read moreGeode Capital Management LLC lowered its stake in shares of Kezar Life Sciences, Inc. (NASDAQ:KZR – Free Report) by 89.4% during the 4th quarter, according to the company in its most recent Form 13F … [+3149 chars]...
Read moreNew York, USA, May 13, 2025 (GLOBE NEWSWIRE) -- Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Met… [+17406 chars]...
Read more